ZAP-70 is a key signaling molecule in T cells. It couples the antigen-activated T-cell receptor to downstream signaling pathways. Its expression in leukemic B-cells derived from a subgroup of patients with chronic lymphocytic leukemia (CLL) is associated with an aggressive course of the disease. However, its implication for the pathogenesis of aggressive CLL is still unclear. In this study, we show that the expression of ZAP-70 enhances the signals associated with the B-cell receptor, recruiting protein kinase C-bII (PKC-bII) into lipid raft domains. Subsequently, PKC-bII is activated and shuttles from the plasma membrane to the mitochondria. We unravel that the antiapoptotic protein Bcl-2 and its antagonistic BH3-protein Bim EL are putative substrates for PKC-bII. PKC-bII-mediated phosphorylation of Bcl-2 augments its antiapoptotic function by increasing its ability to sequester more pro-apoptotic Bim EL. In addition, the phosphorylation of Bim EL by PKC-bII leads to its proteasomal degradation. These changes confer leukemic cells to a more antiapoptotic state with aggressiveness of the disease. Most importantly, these molecular changes can be therapeutically targeted with the small molecule inhibitor Enzastaurin. We provide evidence that this compound is highly active in leukemic cells and augments the cytotoxic effects of standard chemotherapeutic drugs.
Introduction
Over the last couple of decades several surrogate markers have been developed to predict the clinical course of patients with chronic lymphocytic leukemia (CLL). Nearly 10 years ago it became evident that patients with unmutated IgV H genes suffer from a more aggressive disease than those with mutated IgV H genes.
1,2 Lack of immunoglobulin rearrangement is generally associated with advanced clinical stages, unfavorable cytogenetic features and resistance to conventional cytotoxic drugs.
Recently, the expression of the tyrosine kinase ZAP-70, usually expressed in T cells, was shown by gene expression array to be restricted to patients with unmutated CLL. Nowadays, analysis of ZAP-70 expression allows for easy separation of subgroups of CLL patients without the necessity for timeconsuming diagnostics for IgV H mutations. 3 ZAP-70 is a cytoplasmatic protein tyrosine kinase and was originally described to be associated with the T-cell receptor. 4 Following T-cell receptor ligation and autophosphorylation, ZAP-70 is recruited to immunoreceptor tyrosine-based activation motifs and becomes activated through tyrosine phosphorylation. In contrast to T cells, normal B cells use p72
Syk equivalent to ZAP-70 for B-cell receptor signaling (BCR). However, in B-CLL the expression of ZAP-70 is thought to enhance immunoglobulin receptor signaling in spite of the concomitant expression of p72 Syk . 5 Recently, two papers showed that the kinase activity of ZAP-70 is dispensable for the enhancement of BCR-signaling, indicating that ZAP-70 most likely acts as an adapter protein in CLL. 6, 7 Numerous papers have described a defect of CLL cells to undergo the programmed cell death, apoptosis, as being the most important feature driving pathogenesis. Strikingly, CLL cells are characterized by an imbalance of pro-and antiapoptotic proteins, predominantly based on an overexpression of Mcl-1 and Bcl-2. As it was recently discovered, the overexpression of Bcl-2 in CLL cells is based upon a loss of the regulatory miRNAs-15 and 16. 8 In addition, gene promotor hypomethylation may be an alternative way used by leukemic cells to increase the Bcl-2 protein levels. 9 A heavy load of antiapoptotic proteins seems to be a hallmark of CLL and a requirement to establish leukemogenesis, but their regulation in IgV H -mutated and unmutated CLL cells is little understood.
Although the separation of two distinct subgroups in CLL is supported by strong clinical data, it remains largely unknown how these subsets differ on the molecular level. The aim of this study was to elucidate how apoptosis-related proteins and signaling pathways are regulated differently in the two subsets of CLL patients. In this study, we demonstrate that PKC-bII recruitment to lipid rafts is augmented by ZAP-70. Our work revealed significant and functional differences between ZAP-70-positive and -negative cells, related to the expression of phospho-Bcl-2, Bim EL and activated protein kinase-C (PKC). In addition, we show that the pharmacological interference with PKC-b has a high therapeutic impact on CLL and augments the cytotoxicity of conventional chemotherapeutic drugs.
Materials and methods

Cell samples
After informed consent, peripheral blood was obtained from patients with a diagnosis of B-CLL who had not been treated for at least 3 months. At the time of analysis all patients were clinically stable, free from infectious complications and undergoing routine clinical outpatient review.
Separation procedures
Peripheral blood mononuclear cells were isolated from heparinized blood samples by centrifugation over a Ficoll-Hypaque layer (Biochrom, Berlin, Germany) of 1.077 g/ml density. For separation of CLL B cells, peripheral blood mononuclear cells were incubated with anti-CD2 and anti-CD14 magnetic beads (Dynabeads M450, Dynal, Oslo, Norway) according to the manufacturer's instructions. After separation B-cells from CLL patients were 498% pure as assessed by direct immunofluorescence. Cells were harvested under ice-cold conditions and were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum at 37 1C and 5% CO 2 in a fully humidified atmosphere. Normal B-cells were separated by positive selection using anti-CD19 immunomagnetic beads (Dynal AS, Oslo, Norway).
ZAP-70 expression
ZAP-70 expression was quantified on purified CLL cells. To this end, leukemic cells were stained with an anti-CD19-PC5 antibody (Beckman Coulter, Krefeld, Germany), fixed and permeabilized using Fix-and-Perm kit (Caltag, Burlingame, CA, USA). Cells were incubated with AlexaFluor 488-conjugated mAb against ZAP-70 (clone 1E7.2) (Caltag) or an irrelevant isotype control Ab for 30 min, then washed and analyzed by flow cytometry using a Coulter flow cytometer.
Culture conditions
Purified B-cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (PAA, Pasching, Austria), penicillin/streptomycin 50 IU/ml, Na-pyruvate 1 mM, L-glutamine 2 mM, L-asparagine 20 mg/ml, 2-mercaptoethanol 0.05 mM, HEPES 10 mM and MEM nonessential amino-acids 0.7 Â (Invitrogen) at 37 1C and 5% CO 2 in a fully humidified atmosphere.
Reagents and antibodies
The following antibodies were used for immunoblotting and immunoprecipitation as indicated in the experiments: Mcl-1, PKC-bII (clone C-18), Lyn (Santa Cruz Biotechnology, Santa Cruz, CA, USA). XIAP, Bcl-2, Bim, Bax, Bak, PKC-b, ZAP-70 (BD Biosciences, San Jose, CA, USA), phospho-BCL-2 (serine 70), Erk, Cox IV (Cell Signaling Technology, Danvers, MA, USA), b-actin (Sigma-Aldrich, St Louis, MO, USA), phosphoserine 65-Bim (corresponding to human serine 69) (Upstate, Lake Placid, NY, USA).
Chemotherapeutics and small molecule inhibitors were purchased from the following companies: Doxorubicin (SigmaAldrich). Phorbol 12-myristate 13-acetate (PMA), PD98050, Gö 6976, Bis-indolylmaleimide I, Lactacystin (Calbiochem/ Merck, Darmstadt, Germany). LY333,531 (Alexis, Lö rrach, Germany). Enzastaurin was kindly provided by Lilly Company (Indianapolis, IN, USA). Bendamustine was purchased from Mundipharma, Limburg, Germany.
Analysis of apoptosis
Cells to be examined for annexin-V expression were washed with PBS and resuspended with 500 ml binding buffer (Annexin-V FITC kit, Immunotec, Marseille, France) containing 1 ml Annexin-V fluorescin-isothiocyanate stock and 5 ml 20 mg/ml phosphatidyl-inositol to determine the phosphatidylserine exposure on the outer plasma membrane. After incubation for 10 min at room temperature in a light-protected area the specimens were quantified by flow cytometry.
Subcellular fractionation
Cells were resuspended in isotonic mitochondrial buffer containing 210 mM manitol, 70 mM sucrose, 1 mM EDTA and 10 mM HEPES (pH 7.5), supplemented with 1 Â complete protease inhibitor cocktail (Roche, Penzberg, Germany). Mitochondrial and cytosolic fractions were isolated as described earlier. 10 Protein concentration of the lysates was determined by DC Protein Assay (BioRad, Hercules, CA, USA). Mitochondrial (10 mg) and 30 mg of cytosolic fraction were used for immunoblot analysis.
Immunoblotting
To investigate cell proteins via western blot 1-10 Â 10 7 cells were lysed in lysis buffer (10 mM Tris/HCl (pH 7.4), 5 mM EDTA, 130 mM NaCl, 1% Triton, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 and 10 mg/ml of each phenantroline, aprotinine, leupeptine and pepstatine) for 20 min at 4 1C. Lysates were spun at 12 000 r.p.m. for 20 min and supernatants were collected. Protein concentration was assessed by the Bio-Rad assay method (Bio-Rad Laboratories, Hercules CA, USA). Total extracts (40 mg per lane) were subjected to SDS-PAGE and blotting was performed on PVDF membranes (Immobilon-P, Millipore GmbH, Schwalbach im Taunus, Germany).
Purification of raft fractions
Purification of raft fractions has been described. 11 Cells (3 Â 10 7 ) were lysed on ice in 1 ml of 1% Triton in MNE buffer (25 mM MES (pH 6.5), 150 mM NaCl, 5 mM EDTA, 50 mM NaF and 1 mM sodium orthovanadate, and 10 mg/ml each aprotinine, leupeptine and pepstatine and the protease inhibitor mix complete mini (Roche), dounced 10 times, and mixed with 1 ml of 85% sucrose made with MNE buffer. After transfer of the lysate to the centrifuge tube, 2 ml of 35% sucrose in MNE buffer was overlaid, and then 1 ml of 5% sucrose in MNE was overlaid. After centrifugation for 3.30 h at 200 000 g in a Beckman SW50.1 400 ml fractions were collected from the top of the gradient. Protein concentration of each fraction was determined using the Bio-Rad (Hercules, CA, USA) protein assay kit, which is based on the Bradford dye-binding procedure. Fractions were pooled or analyzed individually by SDS-PAGE and western blotting.
Immunofluorescent staining of PKC-bII and mitochondria
For immunofluorescence of PKC-bII and mitochondria, MEC-1 cells were incubated with Mitotracker (Invitrogen, Carlsbad, CA, USA) at a concentration of 200 nM for 30 min at 37 1C. Thereafter, cells were washed twice and incubated for 15 min with 5 mM PMA. After addition washing cells were fixed with paraformaldehyde for 20 min. Permeabilization of cells was achieved by incubating cells for 15 min in RPMI 1540, supplemented with 10% goat serum, 0.05% saponin, 10 mM Hepes buffer pH 7.4 and 10 mM glycine pH 8. PKC-bII was stained with the same antibodies as used for immunoblotting.
Statistical analysis
Data from individual experiments are presented as mean± s.e.m. Statistical significances were determined using the unpaired t-test as appropriate. A P-value o0.05 was considered to be statistically significant.
Results
Sustained signaling through the BCR alters the expression of apoptosis proteins in ZAP-70-positive CLL
The heterogeneity of CLL is characterized by a wide range of clinical courses, ranging from indolent disease, which never requires therapy to a more aggressive and potentially lethal disease. The latter is usually characterized by unmutated IgV H genes and expression of ZAP-70. To analyze whether these differences are associated with a distinct expression of apoptosis-regulating proteins, we investigated the baseline expression of proteins known to be crucial for apoptosis in CLL. Patient characteristics for this analysis are presented in Table 1 .
Bim EL is a pro-apoptotic BH3 only protein able to interact with Bcl-2, whereas its capacity to bind directly to Bax and Bak is still controversial. 12 Like other BH-3 only proteins, the function of Bim EL relies on the expression of either Bax or Bak, which are essential for the initiation of the apoptotic program. Strikingly, we found that the expression of the proapoptotic BH3 protein Bim EL inversely correlated with the expression of ZAP-70, hence ZAP-70-positive CLL cells contain very little Bim EL , whereas ZAP-70-negative samples harbor abundant Bim EL protein ( Figure 1a ). When CLL cases were arbitrarily separated into ZAP-70 negative (o5%), intermediate (o20%) and positive (420%; based on flow cytometry analysis) and the protein expression quantified by using scion image software (Scion Corporation), these differences were statistically significant (Supplementary Figure S1) . As Bim expression is regulated at the transcriptional level by survival signals, 13 we analyzed whether differences in RNA expression account for the diminished protein expression of Bim EL in ZAP-70-positive CLL cells. After RNA extraction and reverse transcription, no significant difference was evident among any of the patients in the Bim RNA expression. All three splice variants (Bim extra large, large and short) were detected by RT-PCR (Supplementary Figure S2) . These results indicate that post-transcriptional mechanisms account for the decrease in Bim EL expression in ZAP-70-positive CLL cells.
In addition to decreased Bim EL levels in ZAP-70-positive cells, we observed a somewhat higher expression of Mcl-1 in these samples ( Figure 1a and Supplementary Figure S3 ). In contrast, no overt differences in expression of Bax or Bak or XIAP were obvious in this analysis.
Of all these proteins, Bcl-2 is the only protein remarkably overexpressed in leukemic cells compared with normal B cells (data not shown). Bcl-2 levels varied interindividually, but no overt difference was evident among patients expressing ZAP-70 versus those lacking it (Figure 1a) , suggesting that the total amount of Bcl-2 does not contribute to the aggressive course of the disease in ZAP-70-positive patients. Furthermore, the expression of Bcl-2 is very stable in dying cells (for example, see Ringshausen and Hahntow 14, 15 ), indicating that the total amount of Bcl-2 is not the crucial factor for cell death. Puzzled by this observation, we investigated whether protein modifications of Bcl-2 are relevant for suppression of apoptosis in CLL. As reported recently, the phosphorylation of Bcl-2 at serine 70 is required for its full antiapoptotic function. 16, 17 We evaluated the expression of mitochondrial phospho-Bcl-2 (ser70) in CLL cells derived from ZAP-70-positive and -negative patient samples. Interestingly, the baseline levels of mitochondrial phospho-(Ser70)-Bcl-2 were higher in ZAP-70-positive CLL cells compared with ZAP-70-negative cells (Figure 1b and quantified in Supplementary Figure S4 ). Importantly, we chose to analyze the expression of Bcl-2 exclusively in the mitochondria because phospho-Bcl-2 shuttles out of the mitochondria into the cytosol; here it is dispensable for apoptosis protection and faces degradation through the proteasome. 18 For this reason the difference in p-Bcl-2 levels was less pronounced in whole cell lysates.
As reported earlier, the majority of CLL cells carrying unmutated IgV H genes signal competently after BCR crosslinking. Sustained signaling through the BCR, possibly activated by binding to an auto-antigen, has been implicated in the pathogenesis of CLL carrying unmutated IgV H genes. In addition, in leukemic cells ZAP-70 can enhance signaling in spite of a dysfunctional kinase activity. As ZAP-70-positive cells are characterized by low levels of Bim EL and higher levels of p-Bcl-2 ( Figures 1a and b) , we hypothesized that this expression pattern could result from signals derived from the BCR. To explore this hypothesis, CLL cells were treated for 15 min with anti-IgM. Subsequently, an increase in phospho-Bcl-2 and a decrease in Bim EL expression could be detected. It is interesting to note that Mcl-1 levels did not change ( Figure 1c ).
PKC-bII is constitutively expressed within lipid-rafts in ZAP-70-positive CLL cells
These data suggested that ZAP-70 positive CLL cells contain little amounts of Bim EL and higher levels of phospho-Bcl-2 because of persistent signals derived from the BCR. The interaction of immunoglobulin receptors with their ligands has been shown to occur within an organized contact zone known as the immune synapse. Formation of the immune synapse is accompanied by a remodeling of the microtube cytoskeleton and associated proteins (reviewed in Viola 19 ). In T cells, ZAP-70 is known to be required for clustering signaling molecules into lipid rafts. 20 We assumed that the expression of ZAP-70 in a subset of CLL patients might also effect the activation of signaling molecules associated with the B-cell receptor.
PKC-bII is known to be overexpressed in CLL cells 21 and to be involved in BCR-mediated signaling. To examine whether the distribution of PKC-bII expressed in membrane microdomains differs between ZAP-70-positive and -negative leukemic cells, we investigated its expression in lipid raft domains. Raft fractions were purified from freshly isolated CLL cells from ZAP-70-positive or -negative patients. Surprisingly, we found that ZAP-70 was constitutively expressed in raft domains. Accordingly, these cells constitutively expressed PKC-bII in lipid rafts, whereas the expression of PKC-bII was negligible in raft fractions of ZAP-70-negative patients (Figure 2a, left panel) . However, PKC-bII was expressed to same amounts in non-raft fractions of both subgroups of patients (Figure 2a, right panel) , excluding that the protein was simply overexpressed in only one subgroup. Accordingly, no differences in PKC-bII expression were evident in whole-cell lysates (data not shown). Because PKC is normally not expressed in lipid rafts unless B cells are stimulated through the B-cell receptor, 22 we contemplated whether the constitutive expression of PKC-bII in lipid raft domains of ZAP-70-positive cells could be related to an enforced recruitment of the protein because of sustained signaling through the B-cell receptor. To prove this hypothesis, ZAP-70-positive CLL cells were stimulated with an 
PKC-bII is a putative Bcl-2 kinase in B-CLL
As a sustained signal through the B-cell receptor alters the expression of Bim EL and Bcl-2 in ZAP-70-positive cells, we sought to test whether this was mediated through the activation of PKC. PMA, is a di-ester of phorbol and capable of activating classical and novel PKC isoforms because of its similarity to diacylglycerol. Exposure of ZAP-70-negative CLL cells to increasing doses of PMA increased the phosphorylation of Bcl-2, whereas total Bcl-2 levels were unaffected (Figure 3a ). In addition, Bim EL expression decreased upon PMA treatment to levels barely detectable by immunoblotting. The decrease of Bim EL was preceded by a shift in its mobility, indicating protein modification; for example, phosphorylation (Figure 3a) . Clearly, low expression levels of Bim EL and higher expression of p-Bcl-2 in ZAP-70-positive cells are a consequence of PKC activation. In fact, PMA treatment of CLL cells resembled stimulation with anti-IgM with regard to the expression of Bim EL and p-Bcl-2. In CLL, PKC-bII is the predominate isoform and is associated with the BCR (Figure 2 ). To prove if PKC-bII is a putative Bcl-2 kinase in CLL, we tested whether it translocated to the mitochondria (the predominant localization of Bcl-2) upon activation. One hour after activation, PKC-bII expression decreased and was virtually undetectable in the cytosol; accordingly the protein was now abundantly found in the mitochondria (Figure 3b ). The translocation of PKC-bII was associated with a marked increase in phospho-serine 70 phosphorylation of Bcl-2 in the same compartment. However, after 24 h the overall levels of PKC-bII dropped in both compartments (Figure 3b ), which might be explained by the inhibitory effect of PKC activators on protein expression after prolonged activation. 23 Notably, phospho-Bcl-2 was not strictly expressed in the mitochondria but able to shuttle into the cytosol. In line with these data, immunofluorescent staining of PKC-bII indicated that the kinase was predominantly expressed in clusters at the cell membrane in untreated cells. Fifteen minutes after activation, the distribution of PKC-bII was then significantly dispersed and co-localized to the mitochondria, which were visualized with the cell permanent MitoTracker thiol-reactive chloromethyl moiety (Figure 3c) .
To confirm the role of PKC-bII as a Bcl-2 kinase in CLL, we used small molecule inhibitors to inhibit PKC isoforms. Bismide I has structural similarities with staurosporine and is a competitive inhibitor for classical and novel PKC isoforms. Gö6976 selectively inhibits calcium-dependent PKC isoforms PKC-a and -b, 24 whereas LY333,531 is a selective PKC-b inhibitor. 25 CLL cells were pre-incubated with these inhibitors one hour before PMA (1 nM) was added to the culture. Immunoblotting for phosphoBcl-2 revealed that all inhibitors attenuated the phosphorylation of Bcl-2 at serine 70; however, the PKC-b-specific inhibitor LY333,531 appeared to be most effective (Figure 3d ).
PKC-bII binds to Bim EL before phosphorylation and proteasomal degradation
To analyze the mechanisms underlying the degradation of Bim EL (Figure 3a) , we used ZAP-70-negative CLL stimulated with PMA. Figure 4 . Based on our results shown in Figure 1 , post-transcriptional mechanisms account for the differences in Bim EL expression in CLL cells. Bim EL ubiquitination and proteasomal degradation have been ascribed to growth factor deprivation and phosphorylation of Bim EL seems to be required for this process. 13, 26 To evaluate the role of PKC for the degradation of Bim EL , CLL cells were treated with PMA for 15 min in the presence of the proteasome inhibitor Lactacystin. Activation of PKC caused a significant shift in mobility (Figure 4a ). To analyze whether this change in its molecular weight was because of protein modification, for example, phosphorylation, a phospho-specific antibody against Bim was used. Phosphorylation of Bim at serine 69 has been shown to precede proteasomal degradation. 27 We observed that activation of PKCs by PMA stimulation caused a dose-dependent phosphorylation of Bim EL at serine 69 in CLL cells disabled of proteasomal function (Figure 4a ). Blockade of PKC-b by LY 333 531 attenuated Bim EL phosphorylation (Figure 4a ). In contrast, inhibition of Erk1/2 by PD 98 050 did not impair phosphorylation of Bim EL at serine 69. Notably, the combined inhibition of PKC-b and Erk1/2 had synergistic effects on the phosphorylation of Bim EL (Figure 4a ), indicating that both kinases are required for full phosphorylation and subsequent degradation of Bim EL .
To address whether PKC-bII can physically interact with either Bcl-2 or Bim EL , co-immunoprecipitation experiments were performed. Cells were either untreated or treated with PMA for 15 min before PKC-bII was immunoprecipitated from CLL cells. Immunoblotting with an antibody against Bim EL or p-Bcl-2 revealed that both proteins bind to PKC-bII (Figure 4b) , further supporting the hypothesis that PKC-bII phosphorylates either protein. The reverse immunoprecipitation, using either p-Bcl-2 or Bim antibodies, confirmed their binding to PKC-bII (data not shown). It is interesting to note that we could also co-immunoprecipitate ZAP-70 through an antibody against PKC-bII (data not shown).
Although the precise mechanism of how BH3 proteins become activated and induce apoptosis still remains a mystery, it is well established that Bcl-2 can inhibit apoptosis by sequestering activator pro-apoptotic proteins, such as Bim, thus preventing oligomerization of Bax and Bak. As we observed that higher levels of phospho-Bcl-2 and low levels of Bim EL are a feature of ZAP-70-positive CLLs, we were interested to know whether the activation of PKC would alter the binding of Bim EL to Bcl-2, thus allowing Bcl-2 to sequester more Bim EL. To address this question, we performed immunoprecipitation of Bcl-2 from whole cell lysates of CLL cells either treated with PMA or Lactacystin (or a combination hereof). As anticipated, endogenous Bim EL could be recovered from Bcl-2 complexes These data illustrate that the phosphorylation of Bim EL does not impair its binding to the antagonistic protein Bcl-2. In addition, they suggest that the antiapoptotic effect of PMA may be Fat least partlyFrelated to an increased sequestering of Bim EL by Bcl-2. It is interesting to note that Bax was not bound to Bcl-2 in B-CLL cells (Figure 4c ).
Phospho-Bcl-2 is important for suppression of apoptosis
We found that Bcl-2 is phosphorylated at serine 70 in freshly isolated CLL cells in correlation with the expression of ZAP-70. To explore whether this phosphorylation is important for the antiapoptotic function in CLL cells, we induced cell death by doxorubicin treatment. As expected, cell death was observed in a dose-dependent manner (Figure 5a ). However, although Bcl-2 levels remained stable over the 24 h time course in this experiment, phosphorylation at serine 70 was significantly diminished in accordance with an increase in apoptotic cells. These data suggest that not the absolute protein levels but posttranslational phosphorylation of Bcl-2 is crucial for suppression of apoptosis in CLL.
To provide further evidence that phoshpo-Bcl-2 confers to an apoptosis resistance in CLL cells, PKCs were activated by PMA treatment in the presence or absence of the cytotoxic agent doxorubicin. PMA treatment sufficiently suppressed spontaneous apoptosis of CLL cells (Figure 5c ) associated with an increase in phospho-Ser70-Bcl-2 levels (Figure 5b) . Doxorubicin killed the majority of CLL cells within 24 h and also decreased the basal expression of phospho-Bcl-2, whereas Bcl-2 levels were almost unaffected. However, CLL cells activated with PMA displayed significant resistance to doxorubicin. Accordingly, phosphorylation of Bcl-2 was only slightly reduced in these cells (Figure 5b ). These data indicate that the phosphorylation of Bcl-2, rather than the total amount of Bcl-2, contributes to the apoptosis defect in B-CLL.
The PKC-b-specific inhibitor Enzastaurin kills B-CLL cells and augments the toxicity of chemotherapeutic drugs
Our data suggest that constitutive activation of PKC-bII is a result of sustained B-cell receptor signaling in ZAP-70-positive CLL cells. Its activity alters the expression of Bim EL and p-Bcl-2 in a way that increases the resistance of leukemic cells toward standard chemotherapeutics. It therefore seems reasonable to target PKC-bII for therapeutic purposes.
Enzastaurin is an acyclic bisindolylmaleimide, which was developed as a selective and specific PKC-b inhibitor. 28 The drug is orally available with minimal toxicity and to date has been tested in several solid and hematological malignancies. 29 Leukemic cells from CLL patients were exposed to increasing PKC-bII in ZAP-70-positive CLL C Meyer zum Büschenfelde et al doses of Enzastaurin for 24 h. As determined by Annexin-V/ phosphatidyl-inositol staining and by measuring the mitochondrial membrane potential delta-c, Enzastaurin killed leukemic cells in a dose-dependent manner with significant induction of apoptosis evident at a dose of 5 mM (Figure 6a ). The proapoptotic effect of Enzastaurin was evident in ZAP-70-positive cells, although not exclusive in this subgroup (data not shown). It is noteworthy that Enzastaurin inhibited the phosphorylation of Bcl-2 at serine 70, whereas the expression of total Bcl-2 or Mcl-1 remained unaffected (Figure 6b) .
Finally, we asked if the combination of Enzastaurin with cytotoxic drugs displayed additional cytotoxic effects compared with monotherapy. CLL cells were cultured in a medium for 48 h either in the presence or absence of increasing doses of vincristine, doxorubicin or bendamustine. These drugs are frequently used for the treatment of indolent B-CLL or transformed Richter's disease. Enzastaurin enhanced the cytotoxic effects of all of these drugs (Figure 6c ), indicating that combined therapies might be beneficial in treating CLL patients. In conclusion, Enzastaurin appears to be an attractive drug for the treatment of ZAP-70-positive CLL, because these patients frequently require therapy and become increasingly resistant to conventional chemotherapeutics over the course of the disease.
Discussion
B-cell receptor (BCR) signaling is important for normal B-cell development, survival and proliferation. However, alterations in the BCR-signaling also contribute to the pathogenesis of numerous B-cell malignancies.
A limited repertoire of immunoglobulin-heavy chain variable genes has been reported for B-cells derived from CLL patients, suggesting that antigens and BCR signaling may be involved in lymphoma development. Signaling through the BCR not only requires binding to antigens, but also recruitment of signaling molecules to specialized membrane microdomains enriched in sphingolipids and cholesterol known as lipid rafts. In this study, we show that constitution of raft proteins in a subset of CLL patients has an immediate effect on the expression of pro-and antiapoptotic proteins required for the longevity of leukemic cells and their chemotherapy resistance. If expressed, ZAP-70 translocates to lipid raft domains in CLL, indicative of a persistent BCR signal. In addition, we found that PKC-bII is constitutively expressed within lipid rafts only in ZAP-70-positive CLL cells, whereas in ZAP-70-negative cells, no constitutive raft expression of PKC-bII was observed (Figure 2a) . No differences among PKC-bII expressions were evident in the nonraft fractions (Figure 2a) or in whole-cell protein lysates (data not PKC-bII in ZAP-70-positive CLL C Meyer zum Büschenfelde et al shown). This important difference in PKC-bII distribution between the two CLL subgroups is reflective of its kinase activity: (1) Resting B cells have little if any constitutive PKC-bII expression in membrane microdomains. 22 However, after IgM stimulation a substantial amount of PKC-bII is recruited to lipid rafts. 22 Our observation that ZAP-70-positive cells have PKC-bII constitutively expressed in lipid rafts which is then recruited together with ZAP-70 upon BCR cross-linking substantiates the sustained activation of the BCR in ZAP-70-positive CLL. (2) It was reported by two groups that ZAP-70 expressed in CLL cells can enhance signaling through the B-cell receptor in spite of its inefficient tyrosine kinase activity. 6, 7 This was associated with an increase in intracellular calcium influx in response to treatment with anti-m. Consequently, the proximity of PKC-bII and ZAP-70 should result in a regional increase in the activity of PKC-bII. To further confirm this hypothesis, it seemed obvious to directly measure and compare PKC-bII activity in both CLL subgroups. However, such an experiment is hampered by 21 were the first to describe that PKC-bII is significantly overexpressed in CLL cells compared with their normal B-cell counterparts. In addition, they reported that PKCbII kinase activity differs among CLL samples. Because only two ZAP-70-positive patients were analyzed, no conclusive correlation between PKC-bII activation and ZAP-70 could be made. The apparent discrepancy between theirs and our work can be explained by the different methods used to assess kinase activity. Abrams et al. 21 analyzed membrane association as a surrogate for PKC activity (in addition to a PKC kinase assay, hampered by the above-mentioned technical issues). Importantly, determination of the amount of membrane-bound PKC-bII is a measure of activated PKC-bII in all cellular compartments including the endoplasmatic reticulum, Golgi apparatus and the nucleus. For instance, we found substantial amounts of PKC-b in the nucleus in CLL cells (data not shown). In contrast, we used subcellular compartmentalization to lipid raft domains and the analysis of downstream targets to assess PKC-b activity. It needs to be emphasized that these two different methods obviously yield different results. The amount of PKC-bII recruited to the lipid raft domains is small compared with the non-raft compartment, but sufficient to modulate the expression of Bim EL and Bcl-2. Crosslinkage of the BCR recruited PKC-bII into the lipid raft domains (Figure 2b ) and produced the same phenotype of Bim EL and phospho-Bcl-2 expression as observed in freshly isolated leukemic cells from the peripheral blood (Figure 1) . Importantly, we did not assess the amount of active PKC-bII outside the lipid raft fractions.
Considering our data, we believe that PKC-bII has a predominate role in ZAP-70-positive CLL. Our hypothesis is strongly supported by experiments using the TCL1 transgenic mouse, which develops a CLL-like disorder resembling the human disease. 30 Clones from TCL1 mice display minimal levels of somatic mutations and show features of auto-reactive B-cells, similar to aggressive human B-CLL. 31 TCL1 transgenic mice develop leukemia within 5-8 months. However, the occurrence of murine leukemia is significantly delayed in mice heterozygous for PKC-b and the CLL-like phenotype is entirely lost when both alleles are knocked out. 32 Higher expression levels of Mcl-1 have been observed in ZAP-70-positive patients and are associated with shorter treatment-free survival. 33 In line with these data, we found higher levels of Mcl-1 in ZAP-70-positive CLL (Supplementary Figure S3) .
One important finding of our work is that higher levels of phospho-(serine 70) Bcl-2 are expressed in ZAP-70-positive B-CLL cells as a result of increased PKC-bII activity. Recently, in a paper published by Perez-Galan et al. 34 higher expression levels of p-Bcl-2 in ZAP-70-positive CLL were observed, supporting our model of constitutive activation of PKC-bII in these cells.
The intriguing question entangled in the observation of higher phospho-Bcl-2 levels is how does the phosphorylation alter the ability of Bcl-2 to block apoptosis? Increased sequestering of pro-apoptotic BH3 proteins would be an obvious explanation and was suggested to account for Bcl-2-Bax interactions in a myeloid cell line. 35 Yet, we were unable to detect Bax bound to Bcl-2 either in quiescent or in PMA-activated cells. However, we found that phospho-and non-phospho-Bim EL was bound to Bcl-2 in CLL cells. Activation of PKC significantly increased the binding of Bim EL to Bcl-2 (Figure 4c) . Therefore, we suggest that one possible mechanism of how the phosphorylation of Bcl-2 enhances its antiapoptotic function in CLL cells is by sequestering higher amounts of Bim EL. Our data support the recent finding that CLL cells are exquisitely sensitive to the BH-3 mimetic ABT-737, explained by the tonical sequestration of Bim by Bcl-2. 36 Importantly, the increased binding of Bim EL did not prevent the overall depletion of the protein caused by PKC activation as it became evident from the analysis of whole protein cell lysates of cells treated with PMA (Figure 4c ).
In line with these data, we could show that the phosphorylation of Bcl-2 (serine 70) was closely related to the susceptibility of cells to undergo apoptosis. Thus, cells containing higher levels of phospho-Bcl-2 were more protected against the killing effects of cytotoxic agents ( Figure 5 ). Importantly, using sidedirected mutagenesis, Ito et al. 16 showed that the phosphorylation of serine 70 of Bcl-2 is not merely an association but a critical and functional protein modification with increased antiapoptotic function. To exclude that additional phosphorylation sides of Bcl-2 contribute to this PKC-dependent 'phenotype', transfection of Bcl-2 mutants into primary B-CLL cells would be required. Unfortunately, those experiments cannot be performed because of the limited life-span of primary CLL cells in culture. Even though these are intriguing questions, the important point of our results is that ZAP-70-positive cells harbor higher levels of phospho-serine 70-Bcl-2 because of the constitutive activation of PKC-bII, resulting in a more apoptosisresistant phenotype compared with ZAP-70-negative CLLs. These data provide a molecular mechanism for the aggressive course of ZAP-70-positive CLL.
A striking finding in our experiments was the detection of abundant Bim EL protein in ZAP-70-negative cells, whereas positive cells expressed only very little Bim EL (Figure 1) . Recently, Iglesias-Serret et al. 37 published that Bim is essential for glucocorticoid-induced apoptosis in CLL and upregulated at the transcriptional level. Longo et al. 38 reported that Bim levels varied between CLL samples, however no further explanation was given for this observation. Based on our data, we assume that in their experiment patients with high Bim levels had ZAP-70-negative CLL. Gene targeting studies in mice revealed that Bim is a critical regulator of lymphocyte homeostasis. Bimdeficient mice display an autoreactive phenotype because of impaired lymphocyte apoptosis 39 and subsequently Bim was characterized as a mediator of BCR-induced apoptosis of selfreactive B-cells. 40 These data underline that Bim is a critical and essential mediator of B-cell apoptosis. However, in leukemic CLL cells it appears that Bim EL needs to be removed from the cell to allow escape from the negative selection enforced by sustained signaling through the BCR, possibly related to binding to auto-antigens. Our data underscore the significance of BCR signaling for the pathogenesis of CLL with unmutated IgV Hgenes and provide an explanation of how this signaling contributes to the apoptosis defect of CLL cells.
Finally, we provide data that targeting PKC-b could be harnessed for therapeutic purposes. Enzastaurin is an oral PKC-b inhibitor already used in clinical trials for cancer patients. The
